TrialID,"Last Refreshed on","Public title","Scientific title",Acronym,"Primary sponsor","Date registration","Date registration3","Export date","Source Register","web address","Recruitment Status","other records","Inclusion agemin","Inclusion agemax","Inclusion gender","Date enrollement","Target size","Study type","Study design",Phase,Countries,"Contact Firstname","Contact Lastname","Contact Address","Contact Email","Contact Tel","Contact Affiliation","Inclusion Criteria","Exclusion Criteria",Condition,Intervention,"Primary outcome","Secondary outcome","Secondary ID","Source Name","Secondary Sponsor","Ethics Status","Ethics Approval Date","Ethics Contact Name","Ethics Contact Address","Ethics Contact Phone","Ethics Contact Email","results yes no","results date posted","results url link","results url protocol","results date completed","results date first publication","results summary","results baseline char","results adverse events","results outcome measures","results ipd plan","results ipd description","Prospective registration","Bridging flag truefalse","Bridged type"
ISRCTN01779485,"13 January 2015","Epidemiology and treatment of soil-transmitted helminthiasis, with particular consideration to strongyloidiasis, in Yunnan province, China","                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",,"Swiss National Science Foundation (SNSF) (Switzerland)",21/08/2008,"  20080821","10/13/2025 16:02:45",ISRCTN,http://isrctn.com/ISRCTN01779485,"Not Recruiting",No,,,Both,01/05/2007,300,Interventional,"Open-label, randomised controlled trial (Not Specified)",,China,,,,,,,"Inclusion criteria: 1. Both males and females, age >=5 years<br>2. Submission of >=1 stool sample for the baseline parasitological survey<br>3. For females, not pregnant, as verbally assessed by medical personnel on the day of treatment<br>4. Absence of major systemic illnesses, as assessed by medical personnel on the day of treatment<br>5. Written informed consent by the head of the household on behalf of the whole family","Exclusion criteria: 1. Presence of any abnormal medical condition, as judged by the medical personnel<br>2. No stool sample submitted for baseline parasitological survey<br>3. Enrolled in any other clinical investigation during the study<br>4. For females: pregnancy","Helminth infections <br>Infections and Infestations","The participants who were diagnosed with helminthiases at the baseline parasitological survey were randomly allocated to the following arms: <br><br>Arm 1: Single-dose albendazole (oral), 200 mg for children aged 5-14 years, and 400 mg for individuals aged >=15 years<br>Arm 2: Single-dose tribendimidine (oral), 200 mg for children aged 5-14 years, and 400 mg for individuals aged >=15 years","1. Reduction of infection prevalence of intestinal helminths, assessed by examination of stool samples 2-4 weeks after drug administration <br>2. Frequency and severity of adverse events were recorded within 24 hours after drug administration","Kato-Katz-derived egg count reduction of common soil-transmitted helminths, assessed 2-4 weeks after drug administration. ",N/A,"Main funder:, Commission for Research Partnership with Developing Countries (KFPE) through the Swiss Agency for Development and Cooperation (SDC) (Switzerland), Other funders:, Voluntary Academic Society (Freiwillige Akademische Gesellschaft) (Switzerland), Janggen-Pöhn Foundation (Janggen-Pöhn-Stiftung) (Switzerland), Chinese Ministry of Science and Technology, through their support to the Key Laboratory of Parasite and Vector Biology of the Chinese Ministry of Health (China) (grant ref: 2005DKA21104), Swiss National Science Foundation (Switzerland) (project numbers PPOOB-102883 and PPOOB-119129)",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT00276224,"19 February 2015","Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia","Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia",,"DBL -Institute for Health Research and Development",12/01/2006,"  20060112","10/13/2025 16:02:45",ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00276224,"Not recruiting",No,"9 Years","15 Years",Both,01/09/2005,480,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",N/A,Zambia," ","Victor Mwanakasale, Ph.d.,M.Sc.",,,,"Tropical Disease Research Centre, Ndola, Zambia","<br>    Inclusion Criteria:all schoolchildren, in grade 2 and 3, at four selected schools -<br><br>    Exclusion Criteria:<br><br>    -<br>   ",,Schistosomiasis;Helminthiases;Anaemia,"Drug: ferrous sulphate (drug)","Urine samples examined for schistsoma haematobium at month 0, 3. 6 and 9;Stool samples examined for schistsoma mansoni at mont 0, 3, 6 and 9;Blood samples examined for haemoglobin level mont 0 and month 9","Any side effects to iron supplementation, measured every week for the first foru weeks after treatment start. Mesured on:;- headache;nausea;vomiting;body weakness;diarrhoea;abdominal pain;others",SRP-ZM-VM-04,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
